Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

NCT02770014 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

43

Enrollment

OTHER

Sponsor class

Stopped Terminated due to Osimertinib approval

Conditions

Epidermal Growth Factor Receptor
Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]